NEW YORK (GenomeWeb News) - Bio-Rad Laboratories said today that it has closed its acquisition of antibody manufacturer AbD Serotec, a division of MorphoSys, for around €53 million ($70 million) in cash.
Bio-Rad announced its intention to acquire the business in December.
AbD Serotec offers more than 15,000 antibodies, kits, and accessories. It has an ISO 9001 and ISO 13485 certified production facility in the UK and additional facilities in Germany and the US.
Norman Schwartz, Bio-Rad's president and CEO, said that the acquisition gives Bio-Rad "total assay solutions that can be validated on many of our research platforms for western blotting, multiplex protein expression, ELISA, and cell sorting."